검색
그림
  • 매출

    Amount of export($)

    0

  • 직원수

    Number of employees

    11

  • 설립년도

    Established Year

    2015

회사로고
  • Name of CompanyBIOWAY
  • Number of employees11
  • CEOKIM JONGWOO
  • Export country United States / Japan / China / United Kingdom / Germany / Italy / France / Ghana / Guam / Greece / Nigeria / South Africa / Netherlands / New Zealand / Taiwan, Province of China / Denmark / Lao People's Democratic Republic / Russian Federation / Lebanon
  • Amount of export($)0
  • Business AreasResearch and Development Business
  • home page bioway.co.kr
  • Date of establishment2015-03-04
  • Certification
  • Major bussiness Development of blood cancer treatment agent and fatty liver therapeutic agent

Company Introduction

Bioway Inc., is a novel drug development company that develops blood cancer treatments based on PI3K-  delta inhibitor and NASH treatments based on SIRT1 activator. We have confirmed Best-in-Class in the fast-  growing blood cancer market (CAGR of 11% or more) and expected to achieve First-in-Class status in the  NASH treatment market as well (CAGR 64% or more). We have published AACR Chicago 2018 a poster based  on pre-clinical results. We are actively engaged in business for license out (L/O). In relation to blood cancer  development, Bioway Inc., has been selected for specialized investment and clinical support projects for new  drug development by the Ministry of Health and Welfare.


Sales Products

manager

  • Vice CSO

    Sanghoon Kwon

    Tel.82-2-3295-5182

    Email.sanghoon@bioway.co.kr

  • Principle Researcher

    Sung Lyea Park

    Tel.82-2-3295-5182

    Email.slpark@bioway.co.kr

  • Financial accounting

    Da Woon Jeong

    Tel.82-2-3295-5182

    Email.dwjeong@bioway.co.kr

Location